Novartis recognized among world's most sustainable companies in Corporate Knights Global 100

NovartisNovartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index at the World Economic Forum in Davos.

"Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility," said Joseph Jimenez, CEO of Novartis. "Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly is a core part of Novartis."

Inclusion in the index is determined using 12 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.

Novartis aims to improve global health. Through our business, we make an important contribution to society: We discover and develop innovative medicines and vaccines. We collaborate with others to help address some of the world's greatest health challenges. To earn the trust of these collaborators and our customers, we need to do business responsibly, in a way that underscores our mission of caring and curing. We work to control and eliminate diseases, pioneer new business approaches to reach under-served patients, and find new treatments to improve health in developing countries. We also care for our associates, strive to positively contribute to our communities, and protect the environment. We conduct business ethically, maintaining a Code of Conduct and governance system to ensure associates uphold our values.

Recent recognition for our corporate responsibility activities includes being listed in the STOXX Global ESG Leaders Index for the third consecutive year; being recognized among the 25 best multinational employers by Great Place to Work® Institute; and being ranked top pharmaceutical company in Fortune's World's Most Admired Companies for the third year in a row.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...